STUDY OF INDOLE SS-68 DERIVATIVE IMPACT ON THE PRIMARY GENERALIZED CONVULSIONS INDUCED BY MAXIMAL ELECTRIC SHOCK, THIOSEMICARBAZIDE AND PILICARPINE

Aim. Study of SS-68 impact on primary generalized convulsions in basic estimation tests of anticonvulsant action of agents.Material and methods. Study of the SS-68 impact on primary generalized convulsions included an estimation of anticonvulsant action with maximal electric shock, thiosemicarbazide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kubanskiĭ nauchnyĭ medit︠s︡inskiĭ vestnik 2017-09, Vol.24 (3), p.17-21
Hauptverfasser: BOGUS, S. K., COVALEV, I. G., GULEVSKAYA, O. N., SUZDALEV, K. F., GALENKO-YAROSHEVSKY, P. A.
Format: Artikel
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim. Study of SS-68 impact on primary generalized convulsions in basic estimation tests of anticonvulsant action of agents.Material and methods. Study of the SS-68 impact on primary generalized convulsions included an estimation of anticonvulsant action with maximal electric shock, thiosemicarbazide and pilocarpine antagonism tests performed on white outbred male mice and rats.Results. SS-68 compound possesses dosage dependent anticonvulsant action in maximal electric shock test indicating its ability to prevent death of 100% animals and its activity in thiosemicarbazide and pilocarpine antagonism tests as well. In the maximal electric shock test SS-68 surpassed sodium valproate in its anticolvulsant activity.Conclusion. Neurotransmitter systems of the brain such as GABA, cholinergic and amino acid stimulant system as well as K+, Na+ and Ca2+ channels of neurons shall be the most possible molecular targets of SS-68 anticonvulsant action. Higher activity of SS-68 comparing with sodium valproate in the maximal electric shock test (increasing GABA content in central nervous system) can be related with its wide range of neurotropic action.
ISSN:1608-6228
2541-9544
DOI:10.25207/1608-6228-2017-24-3-17-21